HOME >> BIOLOGY >> NEWS
Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show

(PHILADELPHIA) Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have staved off heart failure in animals by using gene therapy to shut down the adrenal glands excessive output of fight or flight hormones such as epinephrine and norepinephrine. By blocking GRK2, an important regulatory enzyme, they cut the hormone production that forces the heart to pump too hard, leading to heart failure. Such a novel approach targeting the adrenal gland in addition to the heart provides a potential new strategy against heart failure, and could lead to a new class of drugs.

The researchers, led by Walter Koch, Ph.D., W.W. Smith Professor of Medicine and director of the Center for Translational Medicine in the Department of Medicine at Jefferson Medical College, report their findings February 18, 2007, in an advance online publication in the journal Nature Medicine.

The emphasis has always been in treating right at the heart, says Stephen B. Liggett, M.D., director of the cardiopulmonary genomics program at the University of Maryland School of Medicine, who has written an accompanying editorial. Despite our best efforts, about half of all heart failure patients die within five years of diagnosis, so clearly something new is needed. These results add a completely new dimension to the way physicians might be able to intervene to improve heart failure therapy. When an individuals heart begins to fail, the sympathetic nervous system, attempting to compensate for the weakened heart, goes into overdrive, pumping out increasing levels of stimulants catecholamines such as epinephrine and norepinephrine, making a bad situation worse. The typical treatment beta blockers inhibit the beta adrenergic receptors on the heart, blocking the hormones that force the heart to work overtime.

Dr. Kochs group focused instead on the source of catecholamines the adrenal gland. It discovered that in heart failure,
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
18-Feb-2007


Page: 1 2

Related biology news :

1. Targeting key proteins of carcinogenesis
2. Targeting tumors the natural way
3. Targeting tau: Inflammation study suggests new approach for fighting Alzheimers
4. Best of both worlds -- Targeting a single gene could inhibit bone decay and stimulate bone growth
5. Targeting wolbachia, doxycycline reduces pathology of lymphatic filariasis
6. Targeting lung cancer
7. Targeting the dosage compensation complex
8. Targeting pancreatic cancer
9. Targeting a key enzyme with gene therapy reversed course of Alzheimers disease in mouse models
10. Targeting tumor growth
11. How the adrenal clock keeps the body in synch

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... SOMERSET, N.J. (PRWEB) , ... July 01, 2020 ... ... today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility ... with the company’s existing Japanese clinical supply facility located in Kakegawa, the new ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... R&D, today announced that it has entered into a multi-year contract with ... to support their translational and clinical research strategy to discover and develop ...
(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC , ... that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) ... with severe COVID-19. This is the first study of an XPO1 inhibitor in ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the solution ... history of eSource, the reasons it did not take off as quickly as people ... the industry is moving towards capturing data electronically for clinical trials and then repurposing ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this new technology ... technology of its kind on the market and we were pleased that the IFT ... of traditional cultured ingredients, creating a natural way to extend the shelf life and ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... (PTU) is commonly used to suppress pigment formation in zebrafish embryos, maintaining optical ... team led by Dr MA has been using the zebrafish model to investigate ...
Breaking Biology Technology:
Cached News: